相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors
Martina Puglisi et al.
FUTURE ONCOLOGY (2021)
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2021)
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer
Carolyn E. Haunschild et al.
FUTURE ONCOLOGY (2020)
Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
Romane Florent et al.
CELL DEATH & DISEASE (2020)
The forefront of ovarian cancer therapy: update on PARP inhibitors
M. R. Mirza et al.
ANNALS OF ONCOLOGY (2020)
Newly diagnosed ovarian cancer: Which first-line treatment?
Domenica Lorusso et al.
CANCER TREATMENT REVIEWS (2020)
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review
Zeping Han et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Jerry M. Adams et al.
CELL DEATH AND DIFFERENTIATION (2018)
The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737
Cecile Petigny-Lechartier et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer ROSiA Single-Arm Phase 3B Study
Amit M. Oza et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
The molecular mechanisms of chemoresistance in cancers
Hua-Chuan Zheng
ONCOTARGET (2017)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
Anthony W. Tolcher et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
The BCL-2 protein family, BH3-mimetics and cancer therapy
A. R. D. Delbridge et al.
CELL DEATH AND DIFFERENTIATION (2015)
First Evidence That Oligopyridines, α-Helix Foldamers, Inhibit Mcl-1 and Sensitize Ovarian Carcinoma Cells to Bcl-xL-Targeting Strategies
Celine Gloaguen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: An ex vivo experiment in human serous ovarian carcinoma
Stephanie Lheureux et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time
Maria Vassilakopoulou et al.
LABORATORY INVESTIGATION (2015)
PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced
Abdelghani Jebahi et al.
CANCER LETTERS (2014)
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
James M. Cleary et al.
INVESTIGATIONAL NEW DRUGS (2014)
A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors
Gordana Vlahovic et al.
INVESTIGATIONAL NEW DRUGS (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer
Ignace B. Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin et al.
CLINICAL CANCER RESEARCH (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
Nicoletta Colombo et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Emerging Bcl-2 inhibitors for the treatment of cancer
Asfar S. Azmi et al.
EXPERT OPINION ON EMERGING DRUGS (2011)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
Isabel F. Pinhel et al.
BREAST CANCER RESEARCH (2010)
Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells
Karin Simonin et al.
MOLECULAR CANCER THERAPEUTICS (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Weekly topotecan for recurrent platinum resistant ovarian cancer
Fadi Abushahin et al.
GYNECOLOGIC ONCOLOGY (2008)
Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
Cheol-Min Park et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin
James Witham et al.
CLINICAL CANCER RESEARCH (2007)
Absence of Bcl-X-L down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells
M. Villedieu et al.
GYNECOLOGIC ONCOLOGY (2007)
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:: A Gynecologic Oncology Group study
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2006)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2003)
分享论文
